These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 19732971)

  • 1. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants.
    Hill MN; Hillard CJ; Bambico FR; Patel S; Gorzalka BB; Gobbi G
    Trends Pharmacol Sci; 2009 Sep; 30(9):484-93. PubMed ID: 19732971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants.
    Gorzalka BB; Hill MN
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1575-85. PubMed ID: 21111017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders.
    Gorzalka BB; Hill MN; Hillard CJ
    Neurosci Biobehav Rev; 2008 Aug; 32(6):1152-60. PubMed ID: 18433869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids and emotionality: a neuroanatomical perspective.
    McLaughlin RJ; Gobbi G
    Neuroscience; 2012 Mar; 204():134-44. PubMed ID: 21827834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention.
    Charney DS; Manji HK
    Sci STKE; 2004 Mar; 2004(225):re5. PubMed ID: 15039492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
    Manji HK; Duman RS
    Psychopharmacol Bull; 2001; 35(2):5-49. PubMed ID: 12397885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic implication of cocaine- and amphetamine-regulated transcript (CART) in the treatment of depression.
    Pae CU; Lee C; Paik IH
    Med Hypotheses; 2007; 69(1):132-5. PubMed ID: 17196760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression: a case of neuronal life and death?
    Duman RS
    Biol Psychiatry; 2004 Aug; 56(3):140-5. PubMed ID: 15271581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.
    Hudson CJ; Young LT; Li PP; Warsh JJ
    Synapse; 1993 Mar; 13(3):278-93. PubMed ID: 8497811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants.
    Alhaj H; Wisniewski G; McAllister-Williams RH
    J Psychopharmacol; 2011 Sep; 25(9):1175-91. PubMed ID: 21106608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system and the treatment of mood and anxiety disorders.
    Hill MN; Gorzalka BB
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):451-8. PubMed ID: 19839936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing new treatments for depression and anxiety.
    Chen Z; Yang J; Tobak A
    IDrugs; 2008 Mar; 11(3):189-97. PubMed ID: 18311656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating antidepressants of the future: efficacy and safety.
    Rosenzweig-Lipson S; Beyer CE; Hughes ZA; Khawaja X; Rajarao SJ; Malberg JE; Rahman Z; Ring RH; Schechter LE
    Pharmacol Ther; 2007 Jan; 113(1):134-53. PubMed ID: 17010443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of adult hippocampal neurogenesis: relevance to depression.
    Vaidya VA; Fernandes K; Jha S
    Expert Rev Neurother; 2007 Jul; 7(7):853-64. PubMed ID: 17610392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological characterization and mechanisms of the novel antidepressive- and/or anxiolytic-like substances identified from Perillae Herba].
    Tsuji M; Miyagawa K; Takeuchi T; Takeda H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Aug; 28(4):159-67. PubMed ID: 18800619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotrophic effects of antidepressant drugs.
    Castrén E
    Curr Opin Pharmacol; 2004 Feb; 4(1):58-64. PubMed ID: 15018840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drug targets in the signaling pathways activated by antidepressants.
    Páez-Pereda M
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1010-6. PubMed ID: 15946780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoids in the treatment of mood disorders: evidence from animal models.
    Bambico FR; Duranti A; Tontini A; Tarzia G; Gobbi G
    Curr Pharm Des; 2009; 15(14):1623-46. PubMed ID: 19442178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes.
    Stahl SM
    J Clin Psychiatry; 2003 Jul; 64(7):745-6. PubMed ID: 12934972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.